News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Panel Backs Pfizer Inc. (PFE)'s Drug for Kidney Cancer



12/7/2011 11:14:22 AM

SILVER SPRING, Md., Dec 7 - Pfizer Inc won unanimous expert backing for its Inlyta experimental drug for patients with advanced kidney cancer.

A Food and Drug Administration advisory committee voted 13-0 on Wednesday that the drug, also called axitinib, had a favorable benefit-risk profile for such patients after initial treatment has failed.

Read at Reuters
Read at Wall Street Journal
Read at Business Week
Read at USA Today
Read at Street Insider


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES